Used as a key chiral intermediate in the synthesis of pharmaceutical agents, particularly Sitagliptin, a DPP-4 protease inhibitor for the treatment of type 2 diabetes. Its stereochemistry enables selective interactions in biological systems, making it valuable in developing enantiomerically pure medications. Commonly employed in the preparation of active pharmaceutical ingredients (APIs) where high optical purity is required for efficacy and safety. Also utilized in research and development for optimizing drug candidates targeting metabolic diseases.